Best-in-class canceR dIaGnostic cHip for patient sTratification.
Through advanced microengineering and nanotechnology, we have developed a proprietary microfluidic-based liquid biopsy device, the RUBYchip™ (PCT/EP2016/078406). This technology allows for the isolation of all types of CTCs, keepi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto BRIGHT
Duración del proyecto: 33 meses
Fecha Inicio: 2022-07-08
Fecha Fin: 2025-04-30
Líder del proyecto
RUBYNANOMED LDA
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Through advanced microengineering and nanotechnology, we have developed a proprietary microfluidic-based liquid biopsy device, the RUBYchip™ (PCT/EP2016/078406). This technology allows for the isolation of all types of CTCs, keeping them viable and enabling the analysis of their phenotypic, genetic and functional characteristics, enabling unprecedented frequent monitoring of cancer progression in a minimally invasive and cost-efficient way. Our chip isolates 70% of the very scarce CTCs from a 7.5mL blood sample of a cancer patient in less than 3 h and without the need of sample pre‐processing. This dramatic improvement in the sensitivity compared to competition is enabled by a unique microfilter network embedded in a microfluidic device that separates the CTCs from the healthy cells based on their size and deformability. Furthermore, the RUBYchip enables automation reducing inter-laboratory and inter-user dependence and ensuring reproducible analysis of CTCs.